Generex Biotechnology (OTCMKTS:GNBT – Get Rating) and Pasithea Therapeutics (NASDAQ:KTTA – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitability and analyst recommendations.

Earnings & Valuation

This table compares Generex Biotechnology and Pasithea Therapeutics' revenue, earnings per share and valuation.

Pasithea Therapeutics has lower revenue, but higher earnings than Generex Biotechnology.

Insider and Institutional Ownership

Profitability

This table compares Generex Biotechnology and Pasithea Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for Generex Biotechnology and Pasithea Therapeutics, as provided by MarketBeat.

Risk and Volatility

Generex Biotechnology has a beta of -0.07, meaning that its share price is 107% less volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500.

Summary

Generex Biotechnology beats Pasithea Therapeutics on 5 of the 8 factors compared between the two stocks.

About Generex Biotechnology

(Get Rating)

Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida. On April 23, 2022, an involuntary petition for liquidation under Chapter 7 was filed against Generex Biotechnology Corporation in the U.S. Bankruptcy Court for the Southern District of Florida. On June 6, 2022, the involuntary petition was approved by the Court.

About Pasithea Therapeutics

(Get Rating)

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Receive News & Ratings for Generex Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generex Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.